Dr. Reddy's Launches Nivolumab Biosimilar NIVORZ for Cancer Treatment in India
Dr. Reddy's Laboratories has launched NIVORZ, a biosimilar to Bristol Myers Squibb's Opdivo (nivolumab), in India, marking its entry into the immuno-oncology segment. Developed and manufactured in-house at Hyderabad, NIVORZ received approval from the Drugs Controller General of India for 12 cancer indications, including lung, renal, melanoma, and blood cancers. The intravenous therapy aims to improve patient access to immunotherapy through affordable biosimilars, with the Indian immuno-oncology market projected at around Rs 3,900 crore by 2025.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 41/100.
Outlets measured: news18, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 15 Sept, 12:11 pm. Other outlets followed.